{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T07:34:16Z","timestamp":1795160056604,"version":"4.10.3"},"reference-count":42,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cardiovascular or arteriothrombotic adverse events (CV- or AT-AEs) are reported in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). The incidence and characteristics across different TKI have not been systematically analyzed. We analyzed 531 patients treated with frontline TKIs in different prospective trials: imatinib 400 mg (n = 71) and 800 mg (n = 203), nilotinib (n = 108), dasatinib (n = 106), and ponatinib (n = 43). Characteristics and incidence of new-onset CV-AEs and AT-AEs were analyzed. Poisson regression models assessed factors associated with AE incidence. Median follow-up was 94 months (range, 2-195). Overall, 237 patients (45%) developed CV-AEs and 46 (9%) developed AT-AEs. Hypertension was the most common AE seen in 175 patients (33%; grade 3\/4 in 17%). CV-AE and AT-AE incidence ratios (IRs) with 95% confidence intervals (CIs) were 8.6 (7.6-9.8) and 1.7 (1.2-2.2) per 100 person-years. Among the TKIs, ponatinib showed the highest IR (95% CI) for CV-AEs and AT-AEs at 40.7 (27.9-59.4) and 9.0 (4.1-20.1). In multivariate analysis, ponatinib therapy was associated with increased incidence rate ratio (IRR) for CV-AEs (4.62; 95% CI, 2.7-7.7; P &amp;lt; .0001) and AT-AEs (6.38; 95% CI, 1.8-21.8; P &amp;lt; .0001) compared with imatinib 400. In summary, there is an increased risk of CV-AEs (except hypertension) and AT-AEs in CML patients treated with newer TKIs, particularly with ponatinib. Patients on TKIs must be informed and closely monitored for vascular AEs. These studies were registered at www.clinicaltrials.gov as #NCT00048672, #NCT00038649, #NCT00050531, #NCT00254423, #NCT00129740, and #NCT01570868.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018025874","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T16:54:26Z","timestamp":1552928066000},"page":"851-861","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":122,"title":["Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-168X","authenticated-orcid":false,"given":"Preetesh","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Leukemia,"},{"name":"Division of Cancer Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajwal C.","family":"Boddu","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6350-2206","authenticated-orcid":false,"given":"Graciela M.","family":"Nogueras-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princy","family":"Sam","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hycienth","family":"Ahaneku","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"issue":"1","key":"2020021109191299200_B1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","article-title":"Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"16","author":"Haguet","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"2020021109191299200_B2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med"},{"issue":"6","key":"2020021109191299200_B3","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2020021109191299200_B4","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/leu.2013.320","article-title":"Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib","volume":"28","author":"Mayer","year":"2014","journal-title":"Leukemia"},{"issue":"17","key":"2020021109191299200_B5","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2020021109191299200_B6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.14608","article-title":"Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib","volume":"177","author":"Minami","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"2020021109191299200_B7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1055\/s-0033-1356494","article-title":"Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?","volume":"34","author":"Godinas","year":"2013","journal-title":"Semin Respir Crit Care Med"},{"issue":"17","key":"2020021109191299200_B8","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"2020021109191299200_B9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1183\/09031936.00154210","article-title":"Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia","volume":"38","author":"Dumitrescu","year":"2011","journal-title":"Eur Respir J"},{"issue":"5","key":"2020021109191299200_B10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2020021109191299200_B11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"issue":"6","key":"2020021109191299200_B12","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"2020021109191299200_B13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2020021109191299200_B14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ejh.12096","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study","volume":"90","author":"Levato","year":"2013","journal-title":"Eur J Haematol"},{"issue":"6","key":"2020021109191299200_B15","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"2020021109191299200_B16","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3109\/10428194.2014.994205","article-title":"Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment","volume":"56","author":"Gora-Tybor","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2020021109191299200_B17","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.3324\/haematol.2015.135103","article-title":"Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase chronic myelogenous leukemia patients","volume":"101","author":"Fossard","year":"2016","journal-title":"Haematologica"},{"issue":"21","key":"2020021109191299200_B18","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood.V124.21.3135.3135","article-title":"Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial","volume":"124","author":"Cortes","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2020021109191299200_B19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2010.08.020","article-title":"A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib","volume":"35","author":"Estabragh","year":"2011","journal-title":"Leuk Res"},{"issue":"12","key":"2020021109191299200_B20","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.leukres.2008.03.020","article-title":"An evaluation of the cardiotoxicity of imatinib mesylate","volume":"32","author":"Ribeiro","year":"2008","journal-title":"Leuk Res"},{"issue":"3","key":"2020021109191299200_B21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.leukres.2010.07.011","article-title":"The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia","volume":"35","author":"Marcolino","year":"2011","journal-title":"Leuk Res"},{"issue":"1","key":"2020021109191299200_B22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00280-011-1688-7","article-title":"A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects","volume":"69","author":"Abbas","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2020021109191299200_B23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Br\u00fcmmendorf","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"2020021109191299200_B24","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00280-013-2160-7","article-title":"Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies","volume":"71","author":"Sonnichsen","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2020021109191299200_B25","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/cncr.24927","article-title":"Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors","volume":"116","author":"Johnson","year":"2010","journal-title":"Cancer"},{"issue":"7","key":"2020021109191299200_B26","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol"},{"issue":"1","key":"2020021109191299200_B27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/pds.2630030105","article-title":"The medical dictionary for drug regulatory affairs (MEDDRA)","volume":"3","author":"Wood","year":"1994","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2020021109191299200_B28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"issue":"5","key":"2020021109191299200_B29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"key":"2020021109191299200_B30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","article-title":"Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML","volume":"59","author":"Valent","year":"2017","journal-title":"Leuk Res"},{"key":"2020021109191299200_B31"},{"key":"2020021109191299200_B32"},{"key":"2020021109191299200_B33"},{"key":"2020021109191299200_B34"},{"issue":"10","key":"2020021109191299200_B35","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1038\/s41375-018-0247-1","article-title":"Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?","volume":"32","author":"Aghel","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2020021109191299200_B36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clml.2018.12.004","article-title":"Cardiovascular risk and cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"19","author":"Assun\u00e7\u00e3o","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 2","key":"2020021109191299200_B37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imj.13716","article-title":"Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors","volume":"48","author":"Ross","year":"2018","journal-title":"Intern Med J"},{"issue":"8","key":"2020021109191299200_B38","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00277-017-3012-z","article-title":"Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios","volume":"96","author":"Saglio","year":"2017","journal-title":"Ann Hematol"},{"issue":"8","key":"2020021109191299200_B39","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2020021109191299200_B40","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"20","key":"2020021109191299200_B41","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020021109191299200_B42","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.24360","article-title":"Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/6\/851\/1554731\/advances025874.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/6\/851\/1554731\/advances025874.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:53:42Z","timestamp":1581414822000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/6\/851\/246720\/Analysis-of-cardiovascular-and-arteriothrombotic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,3,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018025874","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,18]]}}}